



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE ATTORNEY DOCKET NO. 24945-0007A

In re patent application of:

Hans-Peter BUCHSTALLER et al.

Confirmation No. 4279

Application No.: 10/532,574

Art Unit: 1615

Filed: April 25, 2005

Examiner: Unassigned

For:

METHYLENE UREA DERIVATIVES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie prior art reference against the claims of the present application.

RELEVANCE STATEMENT

The foregoing documents came to the Applicants' attention during a search of the corresponding international application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached.

TIMING/FEE

The instant Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first official action, therefore, no fee is required in connection with its filing. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Date:

Heller Ehrman LLP

1717 Rhode Island Avenue, NW Washington, D.C. 20036

Telephone:

(202) 912-2000

Facsimile:

(202) 912-2020

Respectfully submitted,

Patricia D. Granados

Attorney for Applicant

Reg. No.: 33,683

Customer No. 26633

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995. Control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number	10/532,574			
Filing Date	April 25, 2005			
First Named Inventor	Hans-Peter BUCHSTALLER et al.			
Group Art Unit	1615			
Examiner Name	Unassigned			
Attorney Docket Number	24945-0007A			

U.S. PATENT DOCUMENTS						
Examiner Cite No. No. No.	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant	
	Number - Kind Code ² (if known)	MM-DD-YYYY		Passages or Relevant Figures Appear		
	A01	4,057,636	11/8/1977	Petersen		
	· A02	5,441,984	8/15/1995	Heath, Jr. et al.		
	<u> </u>					
	 			<u> </u>		
 	 					

		FOREIGN	PATENT DOCU	MENTS		
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	_4
	A03	WIPO 01/38324 A2	5/31/2001	Smithkline Beecham PLC	Figures Appear	T [®]
	A04	WIPO 02/24679 A1	3/28/2002	Bayer Aktiengesellschaft		
	A05	WIPO 02/062750 A1	8/15/2002	Schering Corp.		
	A06	EP 0 839 803 A1	5/6/1998	SS Pharm. Co., Ltd.		
	A07	DE 199 47 457 A1	4/5/2001	Aventis Pharma Deutsch.		
	A08	WIPO 02/12210 A1	2/14/2002	Galderma Research		
	A09	WIPO 02/062763 A2	8/15/2002	Bayer Corp.		
	A10	WIPO 00/61561 A1	10/19/2000	Shionogi Bioresearch		
	A11	WIPO 00/61559 A1	10/19/2000	Shionogi Bioresearch		
. "	A12	WIPO 95/18126 A1	7/6/1995	Fujisawa Pharm. Co.		
	A13	WIPO 02/02534 A1	1/10/2002	Astrazeneca AB		
	A14	WIPO 01/57008 A1	8/9/2001	BASF Aktiengesellschaft		

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.
³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box FT PTO/SB/08A (08-00)

plus sign (+) inside this box PTO/SB/08A (08-00)

WAY 0 8 2006

Supproved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and 15 demark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a control of information unless it contains a valid OMB control number

				TRADE		
Substitute for form 1449A/PTO			Complete if Known			
INICO	DREATION	DIC	OLOCUPE	Application Number	10/532,574	
INFORMATION DISCLOSURE				Filing Date	April 25, 2005	
STATEMENT BY APPLICANT		First Named Inventor	Hans-Peter BUCHSTALLER et al.			
				Group Art Unit	1615	
	(use as many she	eets as	necessary)	Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	24945-0007A	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	A15	ROGER A. SMITH et al., "Discovery of Heterocyclic Ureas as a New Class of Raf Kinase Inhibitors: Identification of a Second Generation Lead by a Combinatorial Chemistry Approach", Bioorganic & Medicinal Chemistry Letters, 2001, pp. 2775-2778, Vol. 11	
	A16	THUTAM P. HOPKINS et al., "Solid-Phase Synthesis of Trisubstituted Guanidines", J. Comb. Chem., 2002, pp. 167-174, Vol. 4	
		·	

Examiner		Date	
Signature	·	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.